Lazard Asset Management
DAWN

Lazard Asset Management’s Day One Biopharmaceuticals DAWN Stock Holding History

Lazard Asset Management’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$201K Sell
9,364
-13,701
-59% -$193K ﹤0.01% 1630
2025
Q4 		$215K Buy
23,065
+8,705
+61% +$72.7K ﹤0.01% 1634
2025
Q3 		$101K Buy
14,360
+595
+4% +$4.09K ﹤0.01% 1688
2025
Q2 		$89K Buy
+13,765
New +$94.7K ﹤0.01% 1890

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Lazard Asset Management's DAWN Position: Q1 2026 in Review

Lazard Asset Management reduced its Day One Biopharmaceuticals (DAWN) stake by 59% in Q1 2026, selling an estimated $193K and leaving 9,364 shares worth $201K. The position accounts for ﹤0.01% of the portfolio, ranked #1630.

Lazard Asset Management first reported a position in DAWN in Q2 2025 and has held it in 4 quarters since. The position peaked at $215K in Q4 2025. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • Lazard Asset Management held 9,364 shares of Day One Biopharmaceuticals worth $201K as of Q1 2026.
  • Lazard Asset Management sold 13,701 Day One Biopharmaceuticals shares in Q1 2026, an estimated $193K.
  • Day One Biopharmaceuticals made up ﹤0.01% of Lazard Asset Management's portfolio in Q1 2026, its #1630 holding.
  • Lazard Asset Management first reported a position in Day One Biopharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • Lazard Asset Management's Day One Biopharmaceuticals position peaked at $215K in Q4 2025.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Lazard Asset Management's 13F filing for Q1 2026, filed 15 May 2026.